Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol.9, pp.1545-1552, 2013 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 9
- Publication Date: 2013
- Doi Number: 10.2147/ndt.s52463
- Journal Name: NEUROPSYCHIATRIC DISEASE AND TREATMENT
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1545-1552
- Keywords: second generation antipsychotics, SGA, atherosclerosis, metabolic, dyslipidemia, LDL-C, HEART-DISEASE RISK, ATYPICAL ANTIPSYCHOTICS, TRIGLYCERIDE LEVELS, WEIGHT-GAIN, LIPID-LEVELS, GENE PON1, ARYLESTERASE, RISPERIDONE, DRUGS, HYPERLIPIDEMIA
- Open Archive Collection: AVESIS Open Access Collection
- Akdeniz University Affiliated: No
Abstract
Background: Second generation antipsychotics (SGAs) are currently the most prescribed drugs in the treatment of schizophrenia. Despite their advantages, which include greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer extrapyramidal symptoms, the concern regarding metabolic abnormalities which might cause cardiovascular diseases during treatment with SGAs have been rising. Paraoxonase 1 (PON1) is an enzyme mostly located on high-density lipoprotein particles, and has been shown to protect or inhibit lipoprotein oxidation. Growing evidence suggests that PON1 plays a key role in the pathophysiology of atherosclerosis.